Drug metabolism in supersomes expressing human recombinant CYP2C18 assessed as enzyme-mediated N-desmethylclozapine metabolite formation at 100 uM after 30 mins measured per nmol of P450 by HPLC analysis
Drug metabolism in supersomes expressing human recombinant CYP2C18 assessed as enzyme-mediated N-desmethylclozapine metabolite formation at 10 uM after 30 mins measured per nmol of P450 by HPLC analysis
Drug metabolism in supersomes expressing human recombinant CYP2C18 assessed as enzyme-mediated clozapine-N-oxide metabolite formation at 10 uM after 30 mins measured per nmol of P450 by HPLC analysis
Drug metabolism in supersomes expressing human recombinant CYP2C18 assessed as enzyme-mediated clozapine-N-oxide metabolite formation at 100 uM after 30 mins measured per nmol of P450 by HPLC analysis
Activity of recombinant human CYP2C18 expressed in Escherichia coli JM109 co-expressing P450 reductase assessed as enzyme-mediated drug metabolism measured as compound remaining after 1 hr by LC-MS analysis
Activity of recombinant human CYP2C18 expressed in Escherichia coli JM109 co-expressing P450 reductase assessed as enzyme-mediated drug metabolism treated with LBH589 measured after 1 hr by LC-MS analysis
Drug metabolism in supersomes expressing human recombinant CYP2C18 assessed as enzyme-mediated cyanide adduct formation at 100 uM after 30 mins measured per nmol of P450 by HPLC analysis in presence of KCN
Activity at human recombinant CYP2C18 expressed in baculovirus-infected BTI-TN-5B1-4 insect cell microsomes assessed as metabolite formation at 5 to 100 uM after 30 mins by HPLC-RA analysis
Activity of human recombinant CYP2C18 assessed as enzyme-mediated drug metabolism treated with 25 uM vorapaxar after 120 mins by LC-MS/MS analysis in presence of NADPH
Activity of human recombinant CYP2C18 assessed as enzyme-mediated 2-hydroxyethyl (1R,3aR,4aR,6R,8aR,9S,9aS)-9-((E)-2-(5-(3-fluorophenyl)pyridin-2-yl)vinyl)-1-methyl-3-oxododecahydronaphtho[2,3-c]furan-6-ylcarbamate formation at 25 uM after 120 mins by LC-MS/MS analysis in presence of NADPH
Drug metabolism in Escherichia coli membranes expressing recombinant CYP2C18 (unknown origin) co-expressed with human NADPH-CPR/bacterial GroEL/GroES assessed as CYP2C18-mediated R-(+)- N-((1-hydroxy-1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-(2-hydroxypropan-2-yl)furan-2-sulfonamide formation at 10 to 100 uM after 120 mins by LC-MS/MS analysis